Opinion

Video

BCG-Unresponsive NMIBC and Treatments

Author(s):

Mark D. Tyson, MD, MPH,Gary D. Steinberg, MD

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options include cystectomy, intravesical chemotherapy, immunotherapy, or clinical trials.

Current Time 0:00
Duration 5:04
Loaded: 3.24%
Stream Type LIVE
Remaining Time 5:04
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Video content above is prompted by the following:

    • When do you consider a patient to have BCG-unresponsive disease?
    • What treatment options are available for BCG-unresponsiveness/intolerance in patients?
    Related Videos
    1 expert is featured in this series.
    Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men
    1 expert is featured in this series.
    The Incidence of Prostate Cancer and Risk of Progression in Black Men
    2 experts are featured in this series.
    The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses
    2 experts are featured in this series.
    The Evolvement of Imaging in ccRCC
    Rebecca A. Campbell, MD, answers a question during a Zoom video interview
    Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
    1 expert in this video
    Comparing Trials Studying Treatment Intensification In mHSPC
    1 expert in this video
    Impact of Robotic Procedures and Apps on Clinic Efficiency
    An Overview of the ARANOTE Trial
    An Overview of the ARANOTE Trial
    1 expert is featured in this series.
    Abiraterone Acetate: Generic and Branded Options
    1 expert is featured in this series.
    A 69-Year-Old Man With Metastatic Hormone Sensitive Prostate Cancer
    Related Content
    Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC
    May 12th 2025

    Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC

    Hannah Clarke
    The phase 3 RC48-C016 trial met its primary end points.
    Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
    May 4th 2025

    Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

    Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
    Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
    Physical function and frailty measures offer distinct insights in patients with bladder cancer
    May 7th 2025

    Physical function and frailty measures offer distinct insights in patients with bladder cancer

    Hannah Clarke
    Data showed that physical function and self-reported frailty assessments were poorly correlated.
    Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025
    May 1st 2025

    Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

    Amy M. Pearlman, MD
    Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.
    FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
    May 5th 2025

    FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

    Hannah Clarke
    The sBLA for NAI was submitted to the FDA in March 2025.
    FDA updates in urology: April 2025
    May 1st 2025

    FDA updates in urology: April 2025

    Hannah Clarke
    A recap of the FDA submissions and regulatory decisions in urology from April 2025.
    © 2025 MJH Life Sciences

    All rights reserved.